Introduction Inaxaplin, an APOL1 inhibitor, represents a targeted therapeutic approach for APOL1-mediated kidney disease (AMKD), a rapidly progressive proteinuric chronic kidney disease (CKD) driven by toxic gain-of-function APOL1 variants (1). Current standard-of-care treatments for AMKD often fail to halt disease progression, leading to an inexor
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Autopsy Findings of Deceased Renal Transplant Recipient
594 Reached8 Comments5 Likes
Renal Fungal Ball with Fluconazole Instillation through a Nephrostomy Tube
3320 Reached32 Comments10 Likes
Woman with Right Flank Pain, Dysuria and Suprapubic Pain
2620 Reached4 Comments3 Likes
Complication of Para-aortic Lymph Node Dissection in Patients with Horseshoe Kidney
438 Reached3 Comments3 Likes